ReviewOncoTargets and therapy2017

Clinical efficacy evaluation of tyrosine kinase inhibitors for non-adenocarcinoma lung cancer patients harboring EGFR-sensitizing mutations.

Xinyu Song et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.